The Outcome of Electrical Cardioversion in Hyperthyroid Induced Atrial Fibrillation.

Autor:	Shah H; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Hanna KS; General Physician, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Kaur H; General Physician, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Alazzeh MS; Orthopaedic Surgery, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Thandavaram A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Channar A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Purohit A; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Shrestha B; Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Patel D; Neurology, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA., Mohammed L; Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Jazyk:	angličtina
Zdroj:	Cureus [Cureus] 2023 Apr 21; Vol. 15 (4), pp. e37928. Date of Electronic Publication: 2023 Apr 21 (Print Publication: 2023).
DOI:	10.7759/cureus.37928
Abstrakt:	Hyperthyroidism is a prevalent cause of atrial fibrillation (AF). High cardiac output with low systemic vascular resistance, driven by hyperthyroidism, is associated with a rapid heartbeat, enhanced left ventricular systolic and diastolic function, and a higher incidence of supraventricular tachyarrhythmias. After returning to euthyroid status, hyperthyroidism-induced AF generally spontaneously reverts to sinus rhythm (SR), and a significant number of patients remain in chronic AF and require electrical cardioversion (ECV). After effective cardioversion, the long-term outcome of hyperthyroidism-induced persistent AF is unknown. Early ECV before the antithyroid medication should be explored for hyperthyroidism-induced AF to reduce the risk of thromboembolic consequences. The recurrence rate of AF between Hyperthyroid and Euthyroid Patients after ECV did not significantly differ. This review article compares the recurrence rate of AF as an outcome of ECV in Hyperthyroid induced atrial fibrillation. Competing Interests: The authors have declared that no competing interests exist. (Copyright © 2023, Shah et al.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu